CT/NG Testing Market Size & Share 2024 - 2032

CT/NG Testing Market Size

CT/NG Testing Market size was valued at USD 1.5 billion in 2023 and is anticipated to witness growth at a CAGR of 7.1% between 2024 and 2032, driven by the increasing incidence of sexually transmitted infections (STIs) coupled with growing awareness and screening programs.

There has been a global increase in the prevalence of sexually transmitted infections, including chlamydia (CT) and gonorrhea (NG). For instance, according to an article published by the World Health Organization in 2023, more than 1 million sexually transmitted infections (STIs) are acquired every day worldwide, the majority of which are asymptomatic. Factors contributing to this rise include changes in sexual behavior, inadequate access to preventive measures, lack of STI education, and evolving patterns of STI transmission. As STI rates continue to escalate, there is a growing need for effective screening and diagnostic tools to detect and manage these infections promptly.
 

Moreover, increased awareness about the prevalence and risks associated with chlamydia (CT) and gonorrhea (NG) infections is driving public health campaigns aimed at educating individuals about the importance of STI screening. These campaigns, often conducted by government health agencies, non-profit organizations, and healthcare providers, raise awareness about the asymptomatic nature of these infections, their potential complications, and the importance of regular testing, especially among sexually active populations and high-risk groups. Therefore, the aforementioned factors drive the adoption of CT/NG testing devices among individuals and healthcare providers.
 

CT/NG testing refers to the diagnostic process used to detect the presence of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections in individuals. These tests are performed on various specimen types, including urine, genital swabs, vaginal swabs, cervical swabs, urethral swabs, and rectal swabs, depending on the anatomical site of infection. CT/NG testing plays a crucial role in identifying and diagnosing these infections, allowing for prompt treatment and prevention of complications.
 

CT/NG Testing Market Trends

• Advancements in test kits and analyzers have been instrumental in driving the adoption of CT/NG testing. These innovations aim to enhance diagnostic performance, patient compliance, and expand access to high-quality testing services.
   
• Ongoing advancements in testing methodologies, particularly nucleic acid amplification tests (NAATs), have led to increased sensitivity and specificity in detecting chlamydia (CT) and gonorrhea (NG) infections. These tests target the genetic material of the pathogens, allowing for the accurate identification of CT and NG DNA/RNA in clinical samples. Improved test performance reduces the likelihood of false-negative or false-positive results, enhancing accuracy and reliability of STD diagnostics.
   
• Additionally, technological innovations have enabled the development of rapid CT/NG testing assays capable of delivering timely results. Rapid diagnostic tests, including point of care testing (POCT) and molecular assays, provide actionable results within minutes to hours, facilitating prompt clinical decision-making and patient management. Expedited test turnaround times are particularly advantageous in clinical settings where timely diagnosis and treatment are critical for preventing disease transmission and complications.
   
• Furthermore, multiplex testing platforms allow simultaneous detection of multiple pathogens, including CT and NG, in a single assay. These platforms leverage advanced molecular techniques, such as polymerase chain reaction (PCR) and nucleic acid hybridization, to detect and differentiate various STI pathogens from a single sample.
   
• Multiplex testing streamlines the diagnostic process, reduces sample volume requirements, and optimizes laboratory workflow efficiency, making it an attractive option for high throughput testing laboratories and integrated STI screening programs.
   

CT/NG Testing Market Analysis

Based on product type, the market is segmented into consumables and instruments/analyzers. The consumables segment held a dominant market share of 74.9% in 2023.
 

• Test kits and assays are essential consumables used in CT/NG testing assays. Test kits are essential consumables utilized in CT/NG testing, offering convenient, all-in-one solutions for sample collection, processing, and detection. These kits typically include components such as swabs for specimen collection, reagents for nucleic acid extraction, test strips and amplification, and assay platforms for result interpretation.
   
• Additionally, test kits are available in various formats, including traditional laboratory-based kits and point-of-care (POC) kits designed for rapid, on-site testing. Manufacturers continue to innovate by introducing user-friendly test kits with improved sensitivity, specificity, and ease of use, catering to the diverse needs of healthcare providers and testing laboratories.
   
• Furthermore, assays represent another crucial category of consumables. Assays utilize molecular techniques, such as polymerase chain reaction (PCR), nucleic acid amplification tests, and nucleic acid hybridization, to detect and quantify chlamydia and gonorrhea nucleic acids in patient samples. Continuous advancements in assay design, formulation, and performance contribute to improved diagnostic accuracy, reliability, and efficiency in CT/NG testing, driving the widespread adoption of these products.
   

Based on test type, the CT/NG testing market is classified into laboratory testing and point-of-care (POC) testing. The laboratory testing segment accounted for the highest market share and was valued at USD 1.1 billion in 2023.
 

• Laboratory tests are typically performed in centralized clinical laboratories equipped with specialized instrumentation and trained personnel. Laboratory-based assays employ advanced diagnostic methodologies including nucleic acid amplification techniques such as PCR, immunodiagnostics, and isothermal nucleic acid amplification technology to detect the genetic material of chlamydia and gonorrhea pathogens within patient specimens.
   
• Additionally, some laboratories utilize antigen detection methods and culture-based techniques for the detection and isolation of chlamydia and gonorrhea bacteria.
   
• Furthermore, these assays offer high sensitivity, specificity, and throughput, making them well-suited for high-volume testing and comprehensive screening programs. Laboratories may also employ automated platforms and workflow solutions to enhance testing efficiency and throughput, further consolidating their dominant position in the Market.
   

Based on technology, the CT/NG testing market is classified into isothermal nucleic acid amplification technology, polymerase chain reaction, immunodiagnostics, and other technologies. The polymerase chain reaction segment is anticipated to grow at a CAGR of 7.4% to reach USD 1.3 billion by 2032.
 

• PCR-based assays offer exceptional sensitivity and specificity in detecting nucleic acids from Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) pathogens. PCR amplifies target DNA sequences present in patient samples, enabling the accurate identification and quantification of CT and NG infections even at low concentrations. This high sensitivity ensures reliable detection of CT/NG infections, reducing the likelihood of false-negative results and supporting timely clinical interventions.
   
• Additionally, PCR technology allows for multiplexing, enabling simultaneous detection of multiple pathogens, including CT and NG, within a single reaction. Multiplex PCR assays streamline the testing process by consolidating multiple tests into one, optimizing laboratory workflow and resource utilization. Multiplexing enhances efficiency and throughput in CT/NG testing laboratories, enabling rapid and cost-effective screening of large numbers of samples without compromising diagnostic accuracy.
   
• Furthermore, this technology is widely adopted and validated for CT/NG testing in clinical laboratories worldwide. Numerous PCR-based assays have received regulatory approvals and certifications from health authorities, ensuring compliance with quality and performance standards. The extensive validation and clinical validation studies conducted on PCR assays demonstrate their reliability, accuracy, and clinical utility in diagnosing CT and NG infections, fostering confidence among healthcare providers and stakeholders, further fueling the segmental growth.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end-use, the CT/NG testing market is categorized into hospitals & clinics, diagnostic laboratories, home care setting, and other end-users. The hospitals & clinics segment is projected to reach USD 1.2 billion by 2032.

• Hospitals and clinics serve as centralized diagnostic facilities equipped with the necessary infrastructure, resources, and expertise to conduct comprehensive CT/NG testing services. These healthcare settings offer a wide range of diagnostic capabilities, including laboratory-based molecular testing, point-of-care (POC) testing, and clinical consultations, enabling efficient and timely detection of chlamydia and gonorrhea infections.
   
• Additionally, hospitals and clinics provide integrated healthcare services encompassing primary care, specialty care, and diagnostic testing under one roof. Patients visiting hospitals and clinics for routine check-ups, screenings, or treatment can conveniently undergo CT/NG testing as part of their healthcare assessment.
   
• This integrated approach enhances patient access to STI testing services, promoting early detection, treatment, and management of CT/NG infections.
   

North America CT/NG testing market size in 2023 was valued at USD 533.4 million and is predicted to grow at a CAGR of 6.6% over the analysis timeframe.
 

• North America boasts advanced healthcare infrastructure, including well-equipped laboratories, healthcare facilities, and diagnostic centers capable of offering a wide range of STI testing services. Accessibility to quality healthcare services facilitates widespread STI testing and screening initiatives across the region.
   
• Additionally, the regions have stringent regulatory standards governing medical devices and diagnostic tests, ensuring the safety, efficacy, and quality of CT/NG testing products. Compliance with regulatory requirements is essential for market entry and product approval, fostering consumer confidence in CT/NG testing solutions, thereby propelling the growth of this market.
   

U.S. CT/NG testing market is anticipated to grow at a CAGR of 6.5% to reach USD 878.9 million by the end of the forecast timeframe.
 

• The U.S. faces a significant burden of chlamydia and gonorrhea infections, with millions of new cases reported annually. For instance, according to the Centers for Disease Control and Prevention, in 2022, more than 2.5 million cases of syphilis, gonorrhea, and chlamydia were reported in the U.S. The prevalence of STIs is particularly notable among sexually active adolescents and young adults, driving the demand for comprehensive STI testing, including CT/NG testing.
   
• Additionally, the U.S. allocates significant healthcare expenditure towards STI prevention, diagnosis, and treatment. Healthcare providers, laboratories, and healthcare systems invest in state-of-the-art diagnostic technologies and testing solutions to meet the growing demand for STI testing, including CT/NG testing.
   

France CT/NG testing market is projected to grow remarkably in the coming years.
 

• France adheres to rigorous quality assurance standards for medical devices and diagnostic tests, ensuring the safety, accuracy, and reliability of CT/NG testing products. Compliance with regulatory requirements and quality standards is essential for market entry and product acceptance in the French healthcare system.
   
• Additionally, the French government supports STI prevention and control efforts through public health policies, awareness campaigns, and funding initiatives. National and regional health agencies collaborate with healthcare providers, laboratories, and community organizations to implement STI testing programs, improve access to testing services, and reduce STI transmission rates.
   

Japan is experiencing high market growth in the CT/NG testing market.
 

• Japan is at the forefront of technological innovation in healthcare, including the development of advanced diagnostic technologies and testing platforms for STIs. Japanese companies invest in research and development to create cutting-edge CT/NG testing assays, point-of-care devices, and molecular diagnostics that offer high sensitivity, specificity, and ease of use.
   
• Additionally, public health campaigns and educational initiatives raise awareness about STIs, promote safer sexual practices, and encourage regular STI testing among the population. Government agencies, healthcare organizations, and advocacy groups collaborate to disseminate information, reduce stigma, and increase STI testing uptake in Japan, driving market demand for CT/NG testing in the country.
   

CT/NG Testing Market Share

The CT/NG testing industry is characterized by the presence of several established and emerging players that offer a variety of products and services across the globe. The market players compete based on factors such as product quality, innovation, regulatory compliance, customer service, and pricing strategies.
 

CT/NG Testing Market Companies

Prominent players operating in the CT/NG testing industry include:

• Abbott Laboratories
• Becton, Dickinson, and Company
• binx health, inc.
• Bioneer Corporation
• Bio-Rad Laboratories, Inc.
• Cepheid
• ELITech Group
• Genetic Signatures
• Hologic, Inc.
• Meridian Bioscience
• Qiagen
• Roche
• Seegene, Inc.
• Thermo Fisher Scientific, Inc.
• VIRCELL S.L.  
   

CT/NG Testing Industry News:

• In May 2022, Abbott announced FDA clearance for its Alinity m STI Assay. The test simultaneously detects and differentiates four common sexually transmitted infections (STIs) including Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG). This product launch helped the company acquire an enhanced customer base and capitalize on emerging opportunities.
   
• In January 2024, Qiagen announced U.S. Food and Drug Administration (FDA) clearance for the NeuMoDx CT/NG Assay 2.0, expanding its test menu for its integrated PCR-based clinical molecular testing systems NeuMoDx 96 and 288 in the U.S. This assay is designed for the direct detection of asymptomatic and symptomatic bacterial infections involving Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). This product approval may help the company generate enhanced revenue and strengthen its market position.
   

The CT/NG testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Consumables
• Instruments/Analyzers

Market, By Test Type

• Laboratory testing
• Point-of-care (POC) testing

Market, By Technology

• Isothermal nucleic acid amplification technology
• Polymerase chain reaction
• Immunodiagnostics
• Other technologies

Market, By End-use

• Hospitals & clinics
• Diagnostic laboratories
• Home care setting
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa